<div>
<h2>Key Points</h2><ul><li>50,000 Class A shares were sold on April 1, 2026, with a transaction value of ~$1.92 million based on a weighted average price of $38.46 per share.</li><li>This disposition represented 100.00% of Mecklenburg's direct Class A Common Stock holdings at the time, reducing his direct Class A position to zero.</li><li>All shares sold were held directly and originated from the conversion of derivative securities; no indirect entities participated in this transaction.</li><li>10 stocks we like better than Hinge Health ›</li></ul><p>On April 1, 2026, Gabriel M.I. Mecklenburg, Director at <strong>Hinge Health</strong> <span class="ticker">(NYSE:HNGE)</span>, executed the sale of 50,000 Class A Common Stock shares for a total consideration of approximately $1.92 million, according to the SEC Form 4 filing.</p><h2 id="transaction-summary">Transaction summary</h2><section><table><tbody><tr><th>Metric</th><th>Value</th></tr><tr><td>Shares sold (direct)</td><td>50,000</td></tr><tr><td>Transaction value</td><td>$1.9 million</td></tr><tr><td>Post-transaction shares (direct)</td><td>0</td></tr><tr><td>Post-transaction value (direct ownership)</td><td>~$0</td></tr></tbody></table></section><p><em>Transaction value based on SEC Form 4 weighted average purchase price ($38.46); post-transaction value based on April 1, 2026 market close ($38.49).</em></p><h2 id="key-questions">Key questions</h2><ul><li><strong>What is the derivative context for this sale?</strong><br/>The 50,000 Class A shares sold originated from the conversion of derivative securities, with the conversion occurring immediately prior to sale, aligning with common liquidity practices among equity holders with substantial vested options.</li><li><strong>How does this transaction affect Mecklenburg's ownership in Hinge Health?</strong><br/>The sale reduced Mecklenburg's direct Class A Common Stock holdings to zero, but he continues to hold 3,268,813 Class B Common Stock shares (direct and indirect), which are fully convertible to Class A shares, supporting ongoing beneficial ownership.</li><li><strong>Is this transaction part of a routine plan or discretionary action?</strong><br/>This transaction is part of a Rule 10b5-1 trading plan adopted by Mecklenburg on Dec. 1, 2025.</li><li><strong>What is the context for transaction pricing relative to market levels?</strong><br/>The weighted average sale price of around $38.46 per share was in line with the April 1, 2026 market close of $38.49, suggesting no price concession for liquidity and reflecting normal market execution for volume at this scale.</li></ul><h2 id="company-overview">Company overview</h2><section><table><tbody><tr><th>Metric</th><th>Value</th></tr><tr><td>Price (as of market close 2026-04-01)</td><td>$38.46</td></tr><tr><td>Market capitalization</td><td>$3.07 billion</td></tr><tr><td>Revenue (TTM)</td><td>$587.86 million</td></tr><tr><td>Net income (TTM)</td><td>-$528.26 million</td></tr></tbody></table></section><p>* 1-year performance is calculated using April 1st, 2026 as the reference date.</p><h2 id="company-snapshot">Company snapshot</h2><ul><li>Delivers digital healthcare solutions for musculoskeletal conditions, including joint and muscle health, acute injury, chronic pain, and post-surgical rehabilitation.</li><li>Operates a software-driven platform that provides care management and support services for musculoskeletal conditions.</li></ul><p>Hinge Health, Inc. is a healthcare technology company specializing in digital musculoskeletal care, leveraging a scalable software platform to address complex joint and muscle conditions.</p><h2 id="what-this-transaction-means-for-investors">What this transaction means for investors</h2><p>Hinge Health stock has been on a rollercoaster of late. Over the last 12 months, shares soared by as much as 80%, before pulling back. Overall, shares have advanced by 23% over the last year. However, they have declined by 15% year to date, driven by broader market weakness.</p><p>The company, which operates in the health technology industry, reported solid fourth-quarter results in February 2026. Revenue increased by 46% year-over-year to $171 million, while free cash flow was $62 million, a 65% year-over-year increase. As a growth stock, Hinge remains focused on expanding its customer base and revenue. Total customers increased 25% to more than 2,800. </p><p>Turning to valuation, Hinge is looking more attractive, as its price-to-sales (P/S) ratio declines as revenue grows. For example, Hinge’s current P/S ratio stands at 5.4x, down from more than 10x in September 2025. </p><p>For growth-oriented investors interested in the health technology sector, Hinge Health is a stock to keep an eye on.</p><h2>Should you buy stock in Hinge Health right now?</h2>
<p>Before you buy stock in Hinge Health, consider this:</p>
<p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Hinge Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $532,066</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,087,496</strong>!*</p>
<p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 926<span>% — a market-crushing outperformance compared to 185% for the S&amp;P 500. <strong><span>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</span></strong></span></p>
<p>See the 10 stocks »</p>
<p style="color: #767676; text-align: left"><em>*Stock Advisor returns as of April 6, 2026. </em></p><p><em>Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.</em></p>
<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
</div>

HNGE

<p>On April 1, 2026, Gabriel M.I. Mecklenburg, Director at Hinge Health, sold 50,000 Class A shares for approximately $1.92 million, reducing his direct holdings to zero. The shares were sold at a weighted average price of $38.46, aligning closely with the market close of $38.49. This transaction was part of a Rule 10b5-1 trading plan. Hinge Health has seen a 23% increase in stock value over the past year, despite a 15% decline year-to-date, and reported a 46% year-over-year revenue increase in Q4 2026.</p>

nasdaq

SPDR S&P Health

Director Sells 50,000 Shares of Digital Health Platform Stock for $1.9 Million, According to Recent SEC Filing